Preventive cardiologyRed Blood Cell Membrane Concentration of cis-Palmitoleic and cis-Vaccenic Acids and Risk of Coronary Heart Disease
Section snippets
Methods
The participants in these analyses were members of the Physicians Health Study (PHS) I and II who provided blood samples from 1995 to 2001. The PHS I is a completed randomized trial designed to study the effects of low-dose aspirin and β-carotene on cardiovascular disease and cancer.16 The PHS II is a randomized trial (started in 1997) designed to study the effects of various vitamins on the risk of cardiovascular disease and cancer.17
In the present ancillary study, we used a prospective nested
Results
The mean age ± SD was 68.7 ± 8.7 years (range 50.4 to 92.0) among the 2,000 study participants. In the control series, the median RBC concentration of cis-palmitoleic and cis-vaccenic acids was 0.49% (interquintile range 0.37% to 0.65%) and 1.69% (interqintile range 1.47% to 2.00%) of the total RBC membrane fatty acid levels, respectively. Compared to those in the lowest quintile, those with a higher quintile of cis-palmitoleic acid had a greater body mass index; greater energy intake; greater
Discussion
In the present prospective nested case-control ancillary study of United States male physicians, we observed a positive association between RBC cis-palmitoleic acid and the 16:1n7/16:0 ratio with CHD risk. Furthermore, RBC cis-vaccenic acid and elongase activity were inversely associated with CHD risk. These findings were robust after additional adjustment of alcohol consumption and energy from carbohydrate and protein—factors that stimulate hepatic DNL.
Limited data are available on the
Acknowledgment
We are indebted to the participants in the Physicians Health Study (PHS) for their outstanding commitment and cooperation and to the entire PHS staff for their expert and unfailing assistance.
References (29)
- et al.
Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding
Am J Clin Nutr
(2008) - et al.
Fatty acids in the de novo lipogenesis pathway and risk of coronary heart disease: the cardiovascular health study
Am J Clin Nutr
(2011) - et al.
Endogenous red blood cell membrane fatty acids and sudden cardiac arrest
Metabolism
(2010) - et al.
Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam study
Am J Clin Nutr
(2011) - et al.
Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: the Atherosclerosis Risk In Communities (ARIC) study
Nutr Metab Cardiovasc Dis
(2003) - et al.
Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study
Am J Clin Nutr
(2008) - et al.
Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) study
Am J Clin Nutr
(2003) - et al.
Effects of dietary palmitoleic acid on plasma lipoprotein profile and aortic cholesterol accumulation are similar to those of other unsaturated fatty acids in the F1B golden Syrian hamster
J Nutr
(2009) - et al.
A simple method for the isolation and purification of total lipids from animal tissues
J Biol Chem
(1957) - et al.
Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride—methanol
J Lipid Res
(1964)
Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes
Am J Clin Nutr
Heart disease and stroke statistics—2011 update: a report from the American Heart Association
Circulation
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association
Circulation
Concept of fat balance in human obesity revisited with particular reference to de novo lipogenesis
Int J Obes Relat Metab Disord
Cited by (0)
The present ancillary study was funded by grant R21HL088081 (to L. Djousse) from the National Heart, Lung, and Blood Institute (Bethesda, Maryland). The Physicians' Health Study is supported by grants CA-34944, CA-40360, and CA-097193 from the National Cancer Institute (Bethesda, Maryland) and grants HL-26490 and HL-34595 from the National Heart, Lung, and Blood Institute (Bethesda, Maryland).